Suppr超能文献

腺苷的双面性:抗心律失常与促心律失常作用

The Janus face of adenosine: antiarrhythmic and proarrhythmic actions.

作者信息

Szentmiklosi A József, Galajda Zoltán, Cseppento Ágnes, Gesztelyi Rudolf, Susán Zsolt, Hegyi Bence, Nánási Péter P

机构信息

Department of Pharmacology and Pharmacotherapy, University of Debrecen, P.O. Box 12, H-4012 Debrecen, Nagyerdei krt. 98. Hungary.

出版信息

Curr Pharm Des. 2015;21(8):965-76. doi: 10.2174/1381612820666141029100346.

Abstract

Adenosine is a ubiquitous, endogenous purine involved in a variety of physiological and pathophysiological regulatory mechanisms. Adenosine has been proposed as an endogenous antiarrhythmic substance to prevent hypoxia/ischemia-induced arrhythmias. Adenosine (and its precursor, ATP) has been used in the therapy of various cardiac arrhythmias over the past six decades. Its primary indication is treatment of paroxysmal supraventricular tachycardia, but it can be effective in other forms of supraventricular and ventricular arrhythmias, like sinus node reentry based tachycardia, triggered atrial tachycardia, atrioventricular nodal reentry tachycardia, or ventricular tachycardia based on a cAMP-mediated triggered activity. The main advantage is the rapid onset and the short half life (1- 10 sec). Adenosine exerts its antiarrhythmic actions by activation of A1 adenosine receptors located in the sinoatrial and atrioventricular nodes, as well as in activated ventricular myocardium. However, adenosine can also elicit A2A, A2B and A3 adenosine receptor-mediated global side reactions (flushing, dyspnea, chest discomfort), but it may display also proarrhythmic actions mediated by primarily A1 adenosine receptors (e.g. bradyarrhythmia or atrial fibrillation). To avoid the non-specific global adverse reactions, A1 adenosine receptor- selective full agonists (tecadenoson, selodenoson, trabodenoson) have been developed, which agents are currently under clinical trial. During long-term administration with orthosteric agonists, adenosine receptors can be internalized and desensitized. To avoid desensitization, proarrhythmic actions, or global adverse reactions, partial A1 adenosine receptor agonists, like CVT-2759, were developed. In addition, the pharmacologically "silent" site- and event specific adenosinergic drugs, such as adenosine regulating agents and allosteric modulators, might provide attractive opportunity to increase the effectiveness of beneficial actions of adenosine and avoid the adverse reactions.

摘要

腺苷是一种广泛存在的内源性嘌呤,参与多种生理和病理生理调节机制。腺苷已被认为是一种内源性抗心律失常物质,可预防缺氧/缺血诱导的心律失常。在过去的六十年中,腺苷(及其前体ATP)已被用于治疗各种心律失常。其主要适应证是治疗阵发性室上性心动过速,但对其他形式的室上性和室性心律失常也可能有效,如窦房结折返性心动过速、触发房性心动过速、房室结折返性心动过速或基于cAMP介导的触发活动的室性心动过速。主要优点是起效迅速且半衰期短(1 - 10秒)。腺苷通过激活位于窦房结和房室结以及激活的心室心肌中的A1腺苷受体发挥其抗心律失常作用。然而,腺苷也可引发A2A、A2B和A3腺苷受体介导的全身性副作用(潮红、呼吸困难、胸部不适),但它也可能表现出主要由A1腺苷受体介导的促心律失常作用(如缓慢性心律失常或房颤)。为避免非特异性全身性不良反应,已开发出A1腺苷受体选择性完全激动剂(替卡地松、塞洛地松、曲贝地松),这些药物目前正在进行临床试验。在用正构激动剂长期给药期间,腺苷受体会内化并脱敏。为避免脱敏、促心律失常作用或全身性不良反应,已开发出部分A1腺苷受体激动剂,如CVT - 2759。此外,药理学上“沉默”的位点和事件特异性腺苷能药物,如腺苷调节剂和变构调节剂,可能为提高腺苷有益作用的有效性并避免不良反应提供有吸引力的机会。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验